CCA
MRNA icon

Childress Capital Advisors’s Moderna MRNA Stock Holding History

Childress Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,176
Closed -$211K – 140
2022
Q4 		$211K Buy
+1,176
New +$192K 0.07% 171
2022
Q2 		– Sell
-1,257
Closed -$217K – 183
2022
Q1 		$217K Buy
1,257
+286
+29% +$48.1K 0.08% 175
2021
Q4 		$247K Buy
971
+17
+2% +$4.97K 0.1% 151
2021
Q3 		$372K Buy
954
+61
+7% +$22.5K 0.15% 125
2021
Q2 		$209K Buy
+893
New +$160K 0.1% 151
2021
Q1 		– Sell
-148
Closed -$15K – 649
2020
Q4 		$15K Buy
+148
New +$15K 0.01% 427

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Childress Capital Advisors's MRNA Position: Q1 2023 in Review

Childress Capital Advisors sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,176 shares — an estimated $211K sold.

Childress Capital Advisors first reported a position in MRNA in Q4 2020 and held it in 6 quarters. The position peaked at $372K in Q3 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Childress Capital Advisors reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Childress Capital Advisors sold 1,176 Moderna shares in Q1 2023, an estimated $211K.
  • Childress Capital Advisors first reported a position in Moderna in Q4 2020 and held it in 6 quarters.
  • Childress Capital Advisors's Moderna position peaked at $372K in Q3 2021.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Childress Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.